138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin.

Authors :: Mehra, N.
Fizazi, K.
Laird, A.D.
Barthélémy, P.
Delva, R.
Dorff, T.
Maruzzo, M.
Stirling, A.
Machiels, J-P.
Dumez, H.
Renard, V.
Albacker, L.A.
Hopkins, J.
Chen, H-C.
Mata, M.
Di Santo, N.
Healy, C.G.
van Oort, I.M.
Buttigliero, C.
de Bono, J.S.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS294-S295. 2p.
Publication Year :: 2020

Subjects :: *CASTRATION-resistant prostate cancer
*DNA damage
*GERM cells
*SOMATIC mutation

Full Text Access

Tools